首页> 外文期刊>Journal of the American Medical Directors Association >Recent Advances in Sarcopenia Research in Asia: 2016 Update From the Asian Working Group for Sarcopenia
【24h】

Recent Advances in Sarcopenia Research in Asia: 2016 Update From the Asian Working Group for Sarcopenia

机译:亚洲肌肉减少症研究的最新进展:亚洲肌肉减少症工作组2016年最新动态

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Sarcopenia was recently classified a geriatric syndrome and is a major challenge to healthy aging. Affected patients tend to have worse clinical outcomes and higher mortality than those without sarcopenia. Although there is general agreement on the principal diagnostic characteristics, initial thresholds for muscle mass, strength, and physical performance were based on data from populations of predominantly Europid ancestry and may not apply worldwide. The Asian Working Group for Sarcopenia (AWGS) issued regional consensus guidelines in 2014, and many more research studies from Asia have since been published; this review summarizes recent progress. The prevalence of sarcopenia estimated by the AWGS criteria ranges between 4.1% and 11.5% of the general older population; however, prevalence rates were higher in Asian studies that used European Working Group on Sarcopenia in Older People cut-offs. Risk factors include age, sex, heart disease, hyperlipidemia, daily alcohol consumption, and low protein or vitamin intake; physical activity is protective. Adjusting skeletal muscle mass by weight rather than height is better in showing the effect of older age in sarcopenia and identifying sarcopenic obesity; however, some Asian studies found no significant skeletal muscle loss, and muscle strength might be a better indicator. Although AWGS 2014 diagnostic cut-offs were generally well accepted, some may require further revision in light of conflicting evidence from some studies. The importance of sarcopenia in diverse therapeutic areas is increasingly evident, with strong research interest in sarcopenic obesity and the setting of malignancy. Pharmacologic interventions have been unsatisfactory, and the core management strategies remain physical exercise and nutritional supplementation; however, further research is required to determine the most beneficial approaches. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
机译:肌肉减少症最近被分类为老年综合症,是健康衰老的主要挑战。与没有肌肉减少症的患者相比,受影响的患者往往具有较差的临床结果和更高的死亡率。尽管在主要诊断特征上已达成共识,但肌肉质量,力量和身体机能的初始阈值是基于主要来自欧洲血统的种群的数据,可能不适用于全球。亚洲肌肉减少症工作组(AWGS)于2014年发布了区域共识指南,此后又发表了更多来自亚洲的研究报告;这篇综述总结了最近的进展。根据AWGS标准估算的肌肉减少症的患病率介于普通老年人群的4.1%至11.5%之间。但是,在使用欧洲老年人骨肉减少症工作组的亚洲研究中,患病率较高。危险因素包括年龄,性别,心脏病,高脂血症,每日饮酒和蛋白质或维生素摄入低;体育锻炼具有保护作用。通过体重而不是身高来调节骨骼肌质量,可以更好地显示老年人在少肌症中的作用并确定少肌症肥胖症。但是,一些亚洲研究发现骨骼肌无明显丢失,而肌肉力量可能是更好的指标。尽管AWGS 2014诊断临界值已被普遍接受,但某些研究可能会根据相互矛盾的证据对它们进行进一步修订。肌肉减少症在各种治疗领域中的重要性日益明显,人们对肌肉减少症和恶性肿瘤的研究兴趣很高。药物干预效果不理想,核心管理策略仍然是体育锻炼和营养补充。但是,需要进一步研究以确定最有益的方法。 (C)2016 AMDA-急性和长期护理医学协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号